Publication
Multidrug resistance in Mycobacterium tuberculosis
Publications associées (50)
From natural product to marketed drug: the tiacumicin odyssey
The first members of the tiacumicin family of antibiotics, encompassing more than 40 compounds, were isolated in 1975. Structurally, the core aglycon is an 18-membered macrolactone having two conjugated diene units, one isolated double bond, 5 stereogenic ...
Royal Soc Chemistry2013Sources, Spreading and Fate of Antibiotic Resistance Genes and Resistant Bacteria in Vidy Bay, Lake Geneva, Switzerland
Increasing numbers of multiresistant bacterial pathogens cause severe health problems on a global scale. Large quantities of bacteria and their resistance genes are discharged into natural environments via human and animal waste. Not much is known so far a ...
EPFL2013Temporal variability of antibiotics fluxes in wastewater and contribution from hospitals
David Andrew Barry, Luca Rossi, Sylvain Coutu
Significant quantities of antibiotics are used in all parts of the globe to treat diseases with bacterial origins. After ingestion, antibiotics are excreted by the patient and transmitted in due course to the aquatic environment. This study examined tempor ...
Public Library of Science2013Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos
Background: In mammals, ABCB1 constitutes a cellular "first line of defense" against a wide array of chemicals and drugs conferring cellular multidrug or multixenobiotic resistance (MDR/MXR). We tested the hypothesis that an ABCB1 ortholog serves as protec ...
Biomed Central Ltd2013Dynamics of antibiotics concentrations in the environment at different time scales
David Andrew Barry, Luca Rossi, Sylvain Coutu, Vera Wyrsch
The aim of this study was to assess the most relevant time scales of antibiotics concentration variations at the sewage treatment plant (STP) inlet and to create a model for the simulation of short-term concentration variations. During one year six antibio ...
2012Malachite Green Interferes with Postantibiotic Recovery of Mycobacteria
John McKinney, Neeraj Dhar, Ekaterina Gelman
The genus Mycobacterium comprises slow-growing species with generation times ranging from hours to weeks. The protracted incubation time before colonies appear on solid culture medium can result in overgrowth by faster-growing microorganisms. To prevent co ...
2012Automated design of ligands to polypharmacological profiles
The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally ...
Nature Publishing Group2012Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers
Hubert van den Bergh, Patrycja Nowak-Sliwinska
Multidrug resistance (MDR) remains a primary hindrance to curative cancer therapy. Thus, introduction of novel strategies to overcome MDR is of paramount therapeutic significance. Sequestration of chemotherapeutics in lysosomes is an established mechanism ...
2012Tuberculosis drugs: new candidates and how to find more
The recent years have witnessed significant progress in the development of new drug candidates for the treatment of TB. While many of these are now in clinical trials, continued research is needed in order to sustain the drug discovery pipeline and meet th ...
2011Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance
Stewart Cole, Joao Pedro De Almeida Neres, Giulia Manina
Summary Tuberculosis is still a leading cause of death in developing countries, for which there is an urgent need for new pharmacological agents. The synthesis of the novel antimycobacterial drug class of benzothiazinones (BTZs) and the identification of t ...
2010